Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ILIAS Biologics

Request full access

Developing engineered exosomes to deliver therapeutic proteins for treating life-threatening diseases

Daejeon, South KoreaFounded 2015

About ILIAS Biologics

ILIAS Biologics, Inc. is a biotechnology company specializing in the development of engineered exosomes, which are tiny vesicles that can deliver therapeutic proteins to intracellular pathways that are otherwise difficult to target. The company operates in the biopharmaceutical market and primarily serves clients in the healthcare and medical research sectors. ILIAS Biologics employs a proprietary platform technology to load large therapeutic payloads inside exosomes, aiming to treat life-threatening and hard-to-treat diseases such as inflammatory bowel disease (IBD) and acute kidney injury (AKI). The company generates revenue through research and development contracts, grants, and strategic partnerships with other biotech firms and research institutions. By leveraging open innovation, ILIAS Biologics is expanding its global network of research and business alliances to maximize its potential in developing novel exosome-based therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
17
Open positions
None listed
Dealroom signal
37.2/100
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2020 $21M $82M HB Investment · Timefolio Asset Management · Meritz Securities · Daishin Securities —
SERIES AEquity / VC May 2018 $17M $68M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

ILIAS Biologics website traffic

Latest recorded traffic for ILIAS Biologics is 3.1K monthly website visits, down 26.2% over the last three months. ILIAS Biologics's team grew 6.3% over the past year.

Latest monthly visits3.1K 3-month web change-26.2% 1-year team growth+6.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ILIAS Biologics in the Daejeon ecosystem

Live from Dealroom

The ILIAS Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • HB Investment
  • Timefolio Asset Management
  • Meritz Securities
  • Daishin Securities
  • Hanyang Securities
  • Kiwoom Securities
  • Dev Sisters Ventures
  • Daedeok Venture Partners
  • Asset One

Other known investors1 additional known investor

  • KAIST ILP
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇰🇷 South Korea100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ILIAS Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ILIAS Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.